Cardiex has kicked off deliveries of its CONNEQT Pulse arterial health monitors in the U.S., reporting strong preorder momentum and a 150% sales increase in December. The company’s strategic operational shifts and pharma partnerships set the stage for sustained growth in 2025.
- Commencement of CONNEQT Pulse deliveries to U.S. customers with strong preorder sales
- 150% month-over-month sales growth in December, sustained into January
- Pharma division secures 1,500 unit commitments and an $8 million trial pipeline
- Launch of CONNEQT App enhances user engagement and health insights
- Operational restructuring in Sydney to deliver $1 million cost savings in 2025
Strong U.S. Market Entry for CONNEQT Pulse
Cardiex has officially commenced deliveries of its CONNEQT Pulse arterial health monitors to customers in the United States, marking a significant milestone for the company’s consumer health ambitions. Following the receipt of an initial 3,000 units from manufacturing partner Andon, with 5,000 more en route, Cardiex transitioned from a preorder model to immediate shipping in mid-January. This shift has catalyzed a notable sales boost, with December preorder sales surging 150% over November and January maintaining this momentum.
Early customer feedback has been overwhelmingly positive, highlighting the device’s user experience and the value of its arterial health insights. The average sales price has been adjusted to a bundled offering of $350, including two cardiologist reports, with over half of customers opting for this premium package. This pricing refinement has not dampened demand, underscoring strong consumer appetite for advanced cardiovascular health monitoring.
Digital Ecosystem and Pharma Partnerships Fuel Growth
Complementing the hardware launch, Cardiex has rolled out the CONNEQT App on both the App Store and Google Play in the U.S. The app serves as a digital health coach, providing users with comprehensive arterial health metrics, guided wellness programs, and the ability to share reports with healthcare professionals. This integrated approach enhances user engagement and positions Cardiex as a leader in personalized cardiovascular health solutions.
On the pharmaceutical front, Cardiex has secured commitments for 1,500 CONNEQT Pulse units across international markets, bolstering a pharma trials pipeline valued at approximately US$8 million. Strategic partnerships with top-tier clinical research organizations and pharmaceutical companies specializing in neurologic disorders have expanded Cardiex’s footprint in clinical trial applications, particularly in cardiovascular safety assessments.
Operational Streamlining and Financial Position
To support its growth trajectory, Cardiex has implemented a significant operational restructuring, centralizing engineering and development teams in Sydney. This move from a predominantly U.S.-based remote workforce is expected to yield approximately $1 million in cost savings over 2025, enhancing operational efficiency and strengthening the company’s financial position.
Financially, Cardiex reported $0.8 million in revenue from traditional medical markets during the quarter, with net cash used in operating activities at $2.94 million. The company closed the quarter with $3.4 million in cash, supplemented by a recent $3.25 million capital raise aimed at scaling manufacturing, marketing, and sales efforts for the CONNEQT Pulse launch.
Regulatory and Product Development Outlook
Looking ahead, Cardiex anticipates expanded regulatory clearances for the CONNEQT Pulse, including TGA approval in Australia and Medsafe clearance in New Zealand by mid-2025, followed by CE marking in Europe later in the year. Concurrently, research and development teams are advancing projects like SphygmoCLOUD and CONNEQT Band, which aim to integrate Cardiex’s vascular biomarker technology into third-party wearables and medical devices.
Preparations are also underway for FDA submission to obtain over-the-counter clearance for the Pulse, leveraging initial usage data collected during the launch phase. These regulatory and product development initiatives are critical to broadening market access and sustaining innovation momentum.
AI Integration Enhances Customer Experience
In a nod to operational innovation, Cardiex introduced 'Zoe,' an AI-powered customer ambassador designed to streamline marketing content creation and provide 24/7 chatbot support. This strategic investment in AI aims to scale customer interactions efficiently while maintaining high service quality, supporting the company’s expanding user base.
Overall, Cardiex’s December quarter update paints a picture of a company successfully transitioning from product development to commercial execution. The combination of strong sales growth, strategic pharma partnerships, operational efficiencies, and regulatory progress positions Cardiex well to capitalize on the growing demand for personalized arterial health monitoring.
Bottom Line?
Cardiex’s early sales momentum and operational efficiencies set a promising stage, but upcoming regulatory approvals and market expansion will be key to sustaining growth.
Questions in the middle?
- Will Cardiex meet its projected US$3.5 million annual run rate by Q3 2025?
- How will regulatory approvals in Australia, New Zealand, and Europe impact international sales?
- What is the potential market uptake for the FDA OTC clearance of CONNEQT Pulse?